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Abstract
The emergence of the highly pathogenic SARS coronavirus (SARS-CoV) has reignited interest in
coronavirus biology and pathogenesis. An emerging theme in coronavirus pathogenesis is that the
interaction between specific viral genes and the host immune system, specifically the innate immune
system, functions as a key determinant in regulating virulence and disease outcomes. Using SARS-
CoV as a model, we will review the current knowledge of the interplay between coronavirus infection
and the host innate immune system in vivo, and then discuss the mechanisms by which specific gene
products antagonize the host innate immune response in cell culture models. Our data suggests that
the SARS-CoV uses specific strategies to evade and antagonize the sensing and signaling arms of
the interferon pathway. We summarize by identifying future points of consideration that will
contribute greatly to our understanding of the molecular mechanisms governing coronavirus
pathogenesis and virulence, and the development of severe disease in humans and animals.
1. Introduction
Viral interactions with the innate immune system play a central role in determining the outcome
of infection. Early control of viral replication by type I Interferons (IFN), complement proteins,
and other innate immune mediators limit viral spread within the host during the early phases
of the disease (Katze et al., 2002). The early innate response also plays an important role in
shaping the downstream adaptive immune response, however an overactive innate immune
response can also result in immune pathology and subsequent tissue damage (reviewed in
(Garcia-Sastre and Biron, 2006)). Within the last decade, it is clear that many viruses encode
specific gene products that antagonize both the innate and acquired arms of the immune
response (Andrejeva et al., 2004; Basler et al., 2000; Cruz et al., 2006; Gale et al., 1997; Meylan
et al., 2005; Parisien et al., 2001; Park et al., 2003; Symons et al., 1995; Xiang et al., 2002; Ye
et al., 2007). Therefore, a detailed knowledge of how specific viruses interact with the host
innate immune system is essential for understanding the molecular mechanisms regulating
virulence, pathogenesis and disease outcomes.
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Coronavirus interactions with the adaptive immune system have been studied in great detail,
however, surprisingly little is known about how these viruses interact with the innate immune
system (La Bonnardiere and Laude, 1983). Although early studies indicated that mutations in
the M glycoprotein of transmissible gastroenteritis virus (TGEV) modulated type I IFN
responses, suggesting that coronaviruses may encode a novel set of gene functions that interface
with the host innate immune response, little effort focused on unraveling the details of
coronavirus innate immune interactions (Charley and Laude, 1988; La Bonnardiere and Laude,
1983). Early experiments showed that variants of mouse hepatitis virus (MHV) are
differentially susceptible to IFN. This may contribute to different pathogenic outcomes,
however little additional experimentation was performed (Taguchi and Siddell, 1985).
However, the SARS coronavirus (SARS-CoV) epidemic of 2003 rekindled a high level of
interest in how coronaviruses interact with the host and whether interactions with the host
innate immune system are important in both the control of viral infection or if these interactions
lead to virus-induced disease.
In this article, we will discuss two components of the innate immune response that are clearly
important for SARS-CoV induced disease; 1) interactions with macrophages (MP) and
dendritic cells (DC), which shape the early innate and adaptive immune responses within the
lung, while also potentially contributing to virus-induced immune pathology, and 2) the type
I IFN system, an essential component of the early innate response to viral infections that appears
to be blocked or evaded by SARS-CoV and other coronaviruses.
2. Dendritic Cells and Macrophages
Dendritic cells and macrophages are first line components of the innate immune network. DCs,
which can be grouped into plasmacytoid (pDC) and myeloid types (mDC), play important roles
in driving both innate and adaptive immune responses to viral pathogens (Akira and Hemmi,
2003; Ito et al., 2005; Nakano et al., 2001). pDCs rapidly respond to viruses or their derivatives
to produce large amounts of type I IFN, which can induce direct antiviral responses and also
modulate other components of the innate and adaptive immune response, such as natural killer
cells and CD8 T cells (Colonna et al., 2004; Diebold et al., 2003) (Cella et al., 1999; Siegal et
al., 1999). Though less robust than pDCs, mDCs can also secrete large amounts of type I IFN
(Laiosa et al., 2006). However, mDCs also play a major role in stimulating acquired immune
responses through their capacity as antigen presenting cells and producers of a wide array of
immunomodulatory cytokines (Laiosa et al., 2006). MPs are potent producers of type I IFNs
and other pro-inflammatory cytokines that induce antiviral protection while also potentially
contributing to immune pathology associated with viral infections (Diamond et al., 2003).
Analysis of the impact of DCs and MPs on SARS-CoV infection will be discussed below.
3. The Type I IFN System
Since its discovery 50 years ago by Isaacs and Lindemann, the IFN system has come to be
recognized as a crucial frontline defense against viral infection (Isaacs and Lindenmann,
1957). IFNs mediate direct antiviral effects that limit viral replication by activating/up-
regulating several well defined antiviral effectors, including PKR and RNaseL, while also
modulating other aspects of the innate and adaptive immune responses through the induction
of a wide array of IFN inducible genes (ISGs) (Stark et al., 1998; Takaoka and Yanai, 2006).
The number pathogens that neutralize IFN, or other key components of the IFN system,
illustrate that this system is essential for the control of a diverse array of viruses and bacteria.
Perhaps the clearest indicator of how important this pathway is to antiviral defense is the sheer
number of IFN avoidance/antagonism strategies that viruses have evolved. These viral IFN
evasion strategies can be roughly segregated into three categories: 1) avoidance, where the
virus shields itself or its byproducts from recognition by the host cell sensors that activate the
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IFN system (Cardenas et al., 2006), 2) suppression of IFN induction, where the virus actively
inhibits the host cell sensor machinery or its downstream signaling molecules to prevent the
initiation of IFN transcription (Cardenas et al., 2006; Hiscott et al., 2006a; Hiscott et al.,
2006b; Lin et al., 2006; Li et al., 2005b; Li et al., 2005a; Meylan et al., 2005), or 3) suppression
of IFN signaling, where viral gene products block signaling events at or downstream of the
type I IFN receptor complex to prevent activation of an antiviral state within the infected cell
or the enhancement of the IFN response by activating late type I IFN genes (Parisien et al.,
2001; Rodriguez et al., 2002). This raises the question of how coronaviruses, which include
human (SARS-CoV, NL63, OC43 and 229E) and animal (MHV, Infectious Bronchitis Virus
(IBV, TGEV, etc.) strains, interact with the type I IFN system. Of these viruses, only 229E has
been shown to induce IFN in infected cells in culture, while viruses such as SARS-CoV and
MHV fail to induce type I IFN responses in cell culture. However, the mechanism for how
Coronaviruses evade the innate immune system is largely unexplored.
There are two major pathways through which cells sense invading viruses and activate the IFN
pathway (reviewed in (Sen, 2001)). Toll like receptors (TLRs), which include TLR3, TLR7,
TLR8 and TLR9, can detect viruses in endosomal compartments as they enter cells, while
cytoplasmic CARD domain containing RNA helicases, RIG-I and Mda5, sense viral RNA in
the cytoplasm. Both pathways are based on sensor interactions with pathogen associated
molecular patterns (PAMPs), such as double stranded RNA which is a byproduct of viral
replication, or structured single stranded RNAs associated with incoming viral genomes, being
common targets. The TLR and cytoplasmic IFN induction pathways do utilize different adaptor
proteins to mediate signaling, with the TLR dependent pathways utilizing TRIF and/or MyD88,
and the cytoplasmic induction pathway utilizing the mitochondrial adaptor protein MAVS/
IPS-1/VISA/CARDIF. (Figure 1) Downstream of the differing adapters, both pathways share
many common signaling molecules and transcription factors, with both pathways ultimately
activating IRF-3, NF-kB, and AP-1 to initiate type I IFN gene transcription. Each of these
pathways will be discussed further with respect to its potential role in coronavirus infection.
4. Host Response to Viral Infection
The human impact of the SARS-CoV epidemic in 2003 led to an intensive research effort to
understand the pathogenesis of SARS-CoV induced disease. Much of this effort focused on
interactions between the virus and immune response within the lung. This effort will be broken
down into patient studies, which are informative, but by their very nature, complex, studies in
animal models, and cell culture based analysis of viral interactions with primary cells or cell
lines, which provide greater experimental control at the cost of potentially oversimplifying the
system.
Several groups analyzed the serum of SARS-CoV infected patients to determine which classes
of cytokines were up-regulated during infection (Jiang et al., 2005; Yu et al., 2005). Zhang et
al. found that IL-6 was up-regulated in serum while IL-8 and TGF-beta were decreased in
SARS patients. They also found that IFNγ, IL-4 and IL-10 were increased only in convalescent
SARS patients (Zhang et al., 2004). Reghunathan et al. found that IP-10 was induced in SARS-
CoV infected patients and there was a correlation between high IP-10 levels and poor patient
outcome (Reghunathan et al., 2005). The authors also found that IL-6, IL-8 and monocyte
chemoattractant protein-1 were highly induced in super-infected patients, with high levels
indicative of a high risk of death. Additionally, microarray-based analysis of RNA derived
from PBMCs from 10 SARS-CoV infected patients demonstrated that the cells were highly
activated and expressing high levels of inflammatory cytokines. However, no IFNα or β
induction was detected in these patients. Though these studies provide valuable information
on the kinetics and type of host cytokine response that occurs in infected humans during SARS-
CoV infection, drawing general conclusions from these studies is difficult due to differences
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in both the timing of study, the patient population analyzed, and the types of assays used to
evaluate cytokine responses.
Several experiments were performed on lung tissue from fatal SARS cases. Most reports used
only a single or a few patients with different times of death, whether it was from acute disease
or a secondary infection, trying to compare their study to a control patient. Chen et al. identified
carbon containing MPs while To et al. found only infection of epithelial cells by in situ and
immunofluorescence (Chen and Hsiao, 2004). Another publication by Chow et al. identifies
lung pneumocytes, but not MPs as the site of virus replication, while yet another identifies a
different lymphocyte population as the main replication target (Chow et al., 2004). Each of
these differs in the type and length of time of infection of tissues used, the fixation technique
for tissue preservation, the type of probe and the technique used to identify viral proteins and
RNA. A recent paper by Nicholls et al. attempts to combine a large set of patient samples using
immunohistochemistry, in situ hybridization, and RT-PCR to build a comprehensive picture
of the infection cycle (Nicholls et al., 2006). They also comment on how false positive or
negatives can arise for several reasons, including: 1) not all lung tissue is homogenous, so using
tissue from one part of the lung versus another can critically change your interpretation, 2)
different probes and techniques have varying levels of sensitivity depending on the age of the
tissue and how it was handled, 3) the age of the individual will alter the immune response and
clearance time of infection, 4) the overall immune status of the individual at the time of infection
(immunocompromised versus healthy) would impact on both the overall levels of viral
replication and the subsequent host inflammatory response to the virus, and 5) the timeframe
from initial symptoms to death may differ significantly between individuals, with individuals
that rapidly progress showing higher levels of virus at the time of death, while individuals that
succumb to infection after an extended period may have little virus present and die due to
secondary causes. Based on their analysis of this large set of patient samples, Nicholls et al.,
concluded that alveolar epithelium and MPs are the primary targets of SARS-CoV in the lung.
They also suggest that pneumocytes may be the initial site of infection, but that MPs take up
virions and disseminate the virus within the lungs. Interestingly, in the 25 patients they tested
that died within two weeks of symptoms, no virus was detected by in situ hybridization or
immunohistochemistry, even in tissues with clear damage. This suggests that viral replication
may not be directly responsible for death in these individuals, raising the possibility that virus-
induced immune pathology may contribute to SARS-CoV induced disease. In fact, since high
levels of pro-inflammatory cytokines and chemokines correlate with poor SARS-CoV outcome
(Reghunathan et al., 2005; Zhang et al., 2004), it is possible that SARS-CoV infection of MPs
or other potent producers of pro-inflammatory cytokines, without high levels of viral
replication, may ultimately lead to virus-induced immune pathology within the lungs of
patients with poor disease outcomes.
5. SARS-CoV in Macrophages and Dendritic Cells
Given their role in maintaining homeostasis within the lungs, as well as their ability to mount
robust innate immune responses, it is important to consider the role of MPs and DCs during
SARS-CoV infection. Several conflicting reports of SARS-CoV replication and IFN induction
in MPs and DCs have been published over the last few years. Early reports showed that SARS-
CoV did not replicate efficiently in purified monocytes and MPs (Yilla et al., 2005). The
infection however was donor dependent, with 100% infection in some donors and less than
5% infection efficiency in others. This study also showed that there was a correlation between
the donor cells that produced high amounts of IFNα in response to SARS-CoV also being less
permissive for productive infection. However, this is not the case for all their donors, with
some producing high levels of IFN and being infected while other produce low levels of IFN
and were not infected. Castilletti et al. also found IFα and γ induced from PBMCs infected
with SARS-CoV, with the most robust responses occurring when the PBMCs were exposed
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to fixed SARS-CoV infected Vero cells (Castilletti et al., 2005). These results suggest that
PBMCs are poorly permissive for SARS-CoV and the authors propose that PBMCs may be
able to detect viral glycoproteins on the surface of cells and that this may be a mechanism for
the apparent immunopathology seen in SARS patients lungs. Results from Spiegel et al., also
demonstrated that both live and U.V. inactivated SARS-CoV could induce type I IFN responses
and cellular maturation in DC cultures (Spiegel et al., 2006), suggesting that productive viral
replication is not required to active anti-viral and/or pro-inflammatory responses in these cells.
Similarly, Law et al. find no replication in their isolated DCs but did find a different cytokine
induction profile (Law et al., 2005). The authors infected DCs with SARS-CoV and analyzed
the effects on cell surface markers and maturation. By electron microscopy virions are seen
inside both immature and mature DCs and small amounts of negative strand RNA were
detectable in those cells, suggesting that some level of viral gene expression was occurring.
However the level of RNA decreased over the course of several days indicating that there was
no productive replication. These studies found no evidence of apoptosis or antiviral cytokines
such as IFN α, β, γ and IL-12; however, they did find significant up-regulation of IP-10,
MIP1α, Rantes and monocyte chemoattractant protein-1 (MCP1). The differences in cytokine
profiles between the Castilleti and Law studies may reflect infection of different cell types,
however, both groups suggest that the up-regulation of pro-inflammatory chemokines may
recruit monocytic cells to sites of infection and be a major cause of lung pathology in patients.
Several other groups have also evaluated whether MPs and/or DCs are targets of SARS-CoV
infection and whether this infection leads to production of pro-inflammatory cytokine
responses that might contribute to virus-induced immune pathology within the lung. Tseng et
al. characterized the effect of SARS-CoV infection on human MPs and DCs (Tseng et al.,
2005). They find that neither cell is permissive to SARS-CoV replication, which is consistent
with the results described above, as well as studies by Ziegler et al (Ziegler et al., 2005). In the
studies by Tseng et al., the MPs and DCs were phenotypically altered after SARS-CoV
exposure. They found no increase of cell death but exposure increases the production of IL-6
and IL-12 upon exposure to a suboptimal dose of lipopolysaccharide (LPS), indicating that
SARS primes the cells to respond to TLR ligands, but did not directly activate the cells. They
also demonstrated that SARS-CoV decreased the phagocytic activity of MPs to FITC-Dextran
while at the same time increasing the ability of DCs to stimulate naïve T cells.
Overall, these studies suggest that neither MPs nor DCs are highly permissive for SARS-CoV
replication. While some groups did not see SARS-CoV associated inflammatory cytokine
induction in MPs or DCs, the overall consensus from this work is that SARS-CoV infection
can lead to either the direct activation or the priming of pro-inflammatory cytokine responses
in these cell types, which may ultimately contribute to the development of virus-induced
immune pathology within the lungs. The effect of viral infection on the induction of antiviral
type I IFN responses in these cell types is less clear cut, since type I IFN induction has been
observed by some groups and not others. This difference may reflect sensitivity differences in
their assays, the cell types that are being evaluated, or even genetic differences in their donor
cohorts. Therefore, further work is needed to determine whether or not SARS-CoV is an
activator of antiviral responses in these cells.
6. Coronavirus Interactions with the Type I IFN system
Type I IFN induction has been observed in some studies of SARS-CoV infected MPs and DCs
(Castilletti et al., 2005). These cell types are capable of mounting type I IFN responses in the
absence of active viral replication, it is unclear whether cells that are productively infected
with SARS-CoV can mount type I IFN responses, and by extension, whether SARS-CoV
actively blocks type I IFN induction or signaling (Yen et al., 2006). The cell line used for most
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virus growth experiments and protein analysis is VeroE6, which lacks a functional IFNβ gene.
Other cell lines have been used to identify the IFN pathways induced during SARS-CoV
infection such as MA104 and CaCo2 cells which are highly permissive for infection (> 90%
infected, yields ~ 107 PFU/ml) and 293 cells which are semi-permissive at best (~ 5-10%
infected; yields of ~ 104–5 PFU/ml). Several laboratories have been using these cell lines to
identify which, if any, cytokines and chemokines are induced during infection.
We have analyzed the Type I IFN response in several cell lines. To investigate whether
IFNβ was induced by SARS-CoV infection we transfected 293T cells with a plasmid containing
the IFNβ promoter followed by luciferase. We found that IFNβ promoter activity was not
induced during the course of an infection, from as early as 6 hours to 48 hours post infection.
(Figure 2) During this time frame, Sendai Virus (SeV) infected cells induced large amounts of
IFNβ promoter activity. We also tested whether MA104 cells, African green monkey kidney
cells that have an intact IFN system secrete IFN when infected with SARS-CoV. We find no
Type I IFN to be secreted from either Urbani infected or Tor2 infected cells. (Figure 3) As a
control, PIV infected MA104 cells produced large amounts of Type I IFN over the course of
the infection.
Cinatl Jr et al. compared intestinal cell lines Caco2 and CL-14 for their cytokine profile via
microarray analysis (Cinatl et al., 2004). They find the SARS-CoV replicates to very high titer,
~ 10^8 TCID50/ml and infected cells show cytopathic effect (CPE) commensurate with virus
titer. Microarray analysis was performed on cells at a single 24 hr time point post infection.
They find no change in IFNα and β but an up-regulation of CXC chemokines, OAS2 and MX.
Interestingly there was no difference in the double stranded RNA activated protein kinase
(PKR). IL-18 and MP migration inhibitory factor (MIF) are down regulated. They extend this
correlation to data seen in some patient samples where they find an up-regulation of IP-10 and
IL-8. Spiegel et al also used Caco2 as well as 293 cells to characterize the innate immune
response to SARS infection, comparing the effects of virus on permissive (Caco2) and less
permissive cells (293T cells) (Spiegel et al., 2006). Although SARS-CoV infection did not
induce IFNs, antiviral genes or IL-6; IP-10 and IL-8 were induced in the permissive Caco2
cells, but not 293 cells. They conclude that early virus growth is probably able to expand rapidly
while suppressing anti-viral genes but still secreting IP-10 and IL-8 to recruit immune cells.
Tang et al. used a human hepatoma cell line Huh7 for comparative infection of the
coronaviruses SARS and 229E(Tang et al., 2005). Using an MOI of 100 TCID50 units, gene
expression profiles were compared at 2hr and 4hr post infection, very early times in the lifecycle
of SARS-CoV. At these early timepoints, IL-8 expression levels were increased while neither
IP-10 nor IFNα/β were significantly up-regulated. Importantly, Huh7 cells have been shown
to be deficient in some antiviral responses which are in conflict with these findings (Lanford
et al., 2003). This likely suggests that Huh7 cells are defective for the double stranded RNA
sensing response, consisting of RIGI and Mda5, which would hamper the useful interpretation
of these results.
In contrast to the results obtained in the studies by Tang, Speigel, and Cinatl, which suggest
that SARS-CoV is a poor inducer of type I IFN responses in productively infected cells,
Okabayashi (Okabayashi et al., 2006) found that SARS-CoV infection of Caco2 cells led to
high levels of IFNα/β, L, IRF7, OAS, ISG20 and Mx transcripts at 1 to 2 days post infection
using real-time PCR. They also reported significant inductions of IL-8, IL-6, SOCS3 and TLRs
4,7 and 9 transcripts. The discrepancy between these different studies might reflect differences
in timing, assay sensitivity, or even different passage histories of the cell types in question.
However, with the exception of the results from Okabayashi, most reports argue that SARS-
CoV is a poor inducer of type I IFN in productively infected cells. We cannot reproduce the
results reported by Okabayashi et al., as SARS-CoV infection in Caco2 and 293 cells did not
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induce expression of IFNα, IFNβ, NFkB or p56 (Figure 4). However in infected cultures, we
also reproduce the noted induction of IP-10 in both cell lines supporting reports by Speigel et
al. At this time, the preponderance of data argue that SARS-CoV infection does not induce
Type I IFNs following productive infection in cell culture.
7. Coronavirus Replication Cycle
SARS-CoV generally does not induce type I IFN in productively infected cells in culture, which
suggests that the virus either suppresses or avoids the induction of type I IFN. In light of these
possibilities, we will discuss the coronavirus replication cycle and then identify several specific
stages where the virus or its derivatives might activate the type I IFN system. Since specific
interactions between coronaviruses and the type I IFN system are poorly understood, much of
this discussion will be based on known mechanisms employed by other viruses.
The SARS-CoV is a single-stranded, positive polarity enveloped virus. The genome is
approximately 29.7 kb long and is associated with the nucleocapsid (N) protein, forming a
ribonucleoprotein (RNP) helical N; the RNP is surrounded by a lipid envelope derived from
internal cellular membranes of the host cell. The envelope possesses three major envelope
proteins: the S glycoprotein, responsible for the receptor recognition and fusion, and the small
envelope protein (E) and the M glycoprotein, which are involved in viral budding and release
(Marra et al., 2003; Rota et al., 2003) (Figure 5). Minor virion components include ORF7a,
ORF7b, ORF6 and ORF3a but these are not essential (Huang et al., 2006; Huang et al.,
2007; Schaecher et al., 2007; Shen et al., 2005). The replicase ORF 1a and ORF 1b encode
critical functions for virus replication and likely encode important virulence determinants
(Eckerle et al., 2006; Sperry et al., 2005).
During the coronavirus life cycle (Figure 6), there are several steps where cellular proteins
could detect viral components (Weiss and Navas-Martin, 2005). Coronavirus entry is thought
to be a three stage process including binding of S glycoprotein to the Angiotensin I converting
enzyme (ACE2) protein, cleavage by cathepsin L and activation of a fusion peptide in S2 that
mediates entry via fusion through endocytic compartments (Simmons et al., 2005). Fusion,
which for SARS happens in an endosomal type structure after cathepsin L cleaves the viral S
glycoprotein, viral RNA, which is tightly bound by the N, is released into the cytoplasm of the
cell. Following viral genome release into the cytosol, the genome is translated into the viral
replicase proteins ORF1a and 1b. These polyproteins are then cleaved by 2 proteases, a Papain
like protease (PLP) and the Main Protease (Mpro), into the individual proteins necessary for
replication. The incoming genomic RNA then serves as a template for the synthesis of full
length and subgenomic length negative strand RNAs that serves as template for mRNA
synthesis. Subgenomic RNA synthesis occurs from discontinuous transcription that joins
leader RNA sequences encoded at the 5′ end of the genome to the body sequences of each
subgenomic RNA. The model of transcription attenuation argues that the replicase binds to the
3′ end of the genomic RNA, transcribes incomplete negative strands that terminate in highly
conserved transcription regulatory sequences (TRS) defined by the sequence ACGAAC,
dissociates and re-associates with the full length template near the 5′ end of the genome to
prime transcription of subgenomic negative strand RNAs containing anti-leader RNA
sequences. The eight different subgenomic negative strands serve as template for the synthesis
of like sized subgenomic mRNA (Brian and Baric, 2005). Replicase, structural and accessory
proteins are produced during this phase of replication at which time the structural proteins M
and E localize to the Golgi Apparatus and transverse to a ER/Golgi intermediate compartment
(ERGIC) where budding occurs. Also during this phase, accessory proteins are produced that
localize throughout the cell.
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During virus production, replicase proteins have been shown to localize to double membrane
vesicles in the cell that are induced during viral replication in both MHV and SARS-CoV
(Brockway et al., 2003; Goldsmith et al., 2004; Gosert et al., 2002; Snijder et al., 2006; van
der Meer et al., 1999). The membranes of which are the site of replication and viral assembly.
How the structural E, M, and S proteins re-localize to these structures is unknown. It has
recently been shown that SARS-CoV E and M proteins do not re-localize to the double
membrane structures while for MHV they do (Snijder et al., 2006). Whether this difference is
cell specific, virus specific or experimentally specific is unknown. Also whether the replicase
proteins are functioning on the inside of the vesicles or in the cytoplasm is unclear.
Once assembly occurs, the virus is secreted using the secretory apparatus of the cell, however,
whether coronaviruses pass through the Golgi stacks or use specialized vesicular routes is
unknown. Once at the cell membrane, the vesicles carrying the virions fuse with the cell surface
and release mature virus into the extracellular space.
8. IFN Sensing of Coronaviruses
During the replication of Coronaviruses, many sentinel sites in the cell’s antiviral machinery
are potentially impacted, yet with the exception of 229E, the majority of coronaviruses that
have been evaluated, fail to induce type I IFN responses (Pitkaranta and Hovi, 1993). Though
the specific mechanisms underlying this immune evasion are not well understood, some
potential mechanisms will be discussed below.
During entry, the fusion of the virion either at the membrane or in a vacuole, releases genomic
RNA into the cytoplasm. Endosome associated TLRs, such as TLR3 or TLR7 may detect
SARS-CoV genomic RNA during entry; alternatively the cytoplasmic RNA sensors, RIG-I
and Mda5 might detect the RNA as it enters into the cytoplasm. However, a specific role for
TLRs or RIG-I/Mda5 in detecting coronaviruses has not been reported, yet several virus
families encode products that antagonize signaling at this level (Kash et al., 2006; Zhou et al.,
2005). Coronaviruses may also encode proteins which block the viral RNA signaling and
sensing pathways. Although specific mechanisms have not been elucidated, it is possible that
the viral genome is sequestered, perhaps by the viral N protein, in such a way that the viral
RNA is shielded from host sensor proteins. Other viral proteins, such as NS1 of influenza and
VP35 of Ebola virus have been shown to block type I IFN induction by interfering with the
ability of host sensor proteins (IRF3, Stat1, RigI, MDA5) to detect incoming virus (Hartman
et al., 2004; Kash et al., 2006).
For many coronaviruses, there is no known mechanism of how they evade the host innate
immune system. It is hypothesized that it is by either 1) actively producing IFN antagonist
proteins, 2) using their own replicase proteins to modify host proteins or by 3) the formation
of double membrane vesicles and compartmentalizing replication and perhaps other
coronavirus RNAs. The use of double membrane vesicles could hide the RNAs produced by
protecting them from the RNA sensing machinery. There may also be a role for N in shielding
the viral RNAs from the dsRNA and ssRNA sensing pathways. Many of these possibilities are
being actively investigated.
In addition to simply avoiding the activation of type I IFN responses by either masking the
viral RNA or sequestering the viral replication complexes into specialized compartments, it is
possible that SARS-CoV or other coronaviruses actively inhibit type I IFN induction or
signaling. Speigel et al demonstrated that SARS-CoV infection failed to activate IFNβ
promoter activity, but that IRF-3 was translocated to the nucleus in SARS-CoV infected cells
(Spiegel et al., 2005). However, SARS-CoV infection interfered with IRF-3 hyper-
phosphorylation, dimer formation, and interactions with its essential co-factor, Chromatin
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binding protein (CBP). The role for a specific viral gene or genes in mediating this antagonism
has not been described and needs to be evaluated in further detail.
To investigate this concept further, 2 recent papers have shown that MHV and SARS do not
block the IRF3 signaling pathway in infected cells. Zhou et al. demonstrated that although
MHV does not induce nuclear translocation of IRF3 or IFNβ gene induction it does not block
these pathways either (Zhou and Perlman, 2007). Subsequent treatment of cells with poly I:C
or Sendai virus post infection allows for proper nuclear import of IRF3 and induction of
IFNβ mRNA. They also show that RIGI, MDA5 and TLR3 are also not inhibited by MHV
infection. Similar results were shown by Versteed et al. for MHV and SARS-CoV (Versteeg
et al., 2007). They also show that MHV does not induce IRF3 nuclear translocation and
IFNα gene induction but that each of these is activated when cells are treated with poly I:C or
Sendai Virus. In addition they show that SARS acts the same way in culture; it does not induce
the IFN sensing pathway but does not block the pathways either. Each hypothesizes that there
may protection via compartmentalization of the replication complexes and replication RNA in
the cell that protects it from being sensed by the anti-viral machinery. Versteeg et al. also
proposes that since the 5′ end of SARS RNA is capped it is protected from recognition by RIGI
since it was recently shown that RIGI specifically binds to free phosphates at the 5′ end of the
RNA (Hornung et al., 2006; Pichlmair et al., 2006). This may be another level of protection
SARS-CoV uses to block its sensing from the cellular anti-viral machinery.
We have shown similar data for SARS infections in vitro. We find that SARS infection does
not induce IFNβ or NFkB gene induction, however, they do not block those pathways either
(Figure 7a and b). Promoters of IFNβ and NFkB were assayed for their ability to drive luciferase
expression after infection by SARS. Wildtype SARS infection of cells does activate the
induction of the either of the promoters however each could be activated post infection by
polyI:C (data not shown), exogenous IFNβ (data not shown) or Sendai Virus (Figure 7a and
b) similar to Zhou et al. and Versteed et al. We created recombinant SARS viruses deleted for
each of the SARS accessory ORFs; ORF3a, 3b, 3ab, 3ab/6, 6, 7a, 7b, 8b and 9b. We
hypothesized a SARS-CoV accessory ORF may be mediating the IFN sensing block in vivo.
However we find that similar to wildtype SARS-CoV, all the deletions fail to induce any of
the promoters analyzed above. All of the deletions also allowed for induction post infection
by Sendai virus and poly I:C of the IFNβ, NFkB and p56 promoters assayed. Our data combined
with Zhou et al. and Versteeg et al. lead us to hypothesize that there is a mechanism by which
MHV and SARS-CoV evade detection of by innate immune system by 1) sequestering the viral
genome on membranous replication complexes, 2) capping viral RNA to evade detection by
one arm of the dsRNA sensing machinery and 3) potentially actively inhibiting the innate
immune system by the function of virally encoded proteins. One caveat to this work is that
SARS-CoV could be inhibiting IFN signaling pathways that are detrimental to its own
replication and survival but not inhibiting different pathways inducible by SeV and poly I:C.
In vivo experiments where putative viral antagonists are debilitated or where replication
complexes are retargeted to new sites (ex. autophagy mutants that don’t produce double
membrane vescicles) may provide insight into which of these hypotheses are most likely.
Recent work by Kopecky-Bromberg et al. has identified 3 SARS proteins, ORF3b, ORF6 and
the N protein, that interact with the different elements of the IFN sensing machinery and may
add another layer of protection from the innate immune system (Kopecky-Bromberg et al.,
2006). When expressed in 293 cells from a plasmid, each viral ORF not only blocked expression
from an IFNβ and IRF3 promoter reporter plasmid but also blocked IRF3 phosphorylation. N
expression blocked NFkB promoter induction while ORF3b and 6 did not, demonstrating an
interesting difference in their IFN blocking mechanism. One other distinction between the 3
genes is that all 3 blocked expression from an ISRE promoter reporter construct when the cells
were stimulated with Sendai Virus, but only 3b and 6 blocked induction of the ISRE reporter
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when the cells were treated with IFNβ. Shown in figure 8a, ORF6 expressed in 293 cells
blocked induction of an ISRE promoter expressing luciferase in response to IFNβ treatment.
These data suggested a direct block of the IFN amplification side of the innate immune
pathway; from the IFNα/β receptor to STAT1 nuclear translocation to induction of STAT1
transcribed genes (assayed by the ISRE promoter construct). ORF6 expression does not effect
STAT1 phosphorylation but ORF6 blocked nuclear localization of Stat1 after the cells were
treated with IFNβ (Figure 8b and c) This data shows that each of the 3 genes blocks IFN sensing
and signaling in a different way, enabling a reduction in the anti-viral induction pathways from
several different pathways.
A report from Cervantes-Barragan et al. may also connect the differences seen in cell lines
versus in vivo experiments (Cervantes-Barragan et al., 2006). They have found that there is a
rapid induction of type I IFNs upon MHV infection of pDCs compared to cDCs that coincided
with a block in virus replication. They also show that SARS-CoV reacts similarly as MHV to
different types of DCs (cDC vs. pDC). They identify a potential mediator of the IFN induction
as well. They find that TLR7 seems to be key to the rapid induction seen in pDCs since TLR7
−/− pDCs could produce IFN in response to CpG DNA and not MHV. This result shows that
TLR7 is not needed for CpG DNA induced IFN induction but the lack of TLR7 inhibited the
induction of IFN by MHV. TLR7 may be sensing the MHV virion or replication products to
activate the IFN response in cells.
9. Remaining Questions about Coronavirus Evasion of the Innate Immune
System
Many issues remain unanswered concerning how coronaviruses evade the immune response
during infection. With the technology of reverse genetic systems for MHV, SARS-CoV, HCV
229E and TGEV, specific mutations can be made in the viruses to assess individual proteins’
role in immune evasion and pathogenesis. The continued identification of proteins in the
signaling pathways described above only adds to the abundance of potential host proteins that
may be targeted by viral proteins. Additionally, increased knowledge of pathway inter-
regulation and protein:protein interaction networks expand the possible ways that viral
pathogens modulate the host response to infection. With these new tools we will be able to
gain insight into the critical questions.
1. Which host sensor proteins recognize SARS-CoV genomic RNA or mRNA or viral
dsRNA?
2. How do coronaviruses protect their RNA from RNA sensing enzymes in the cell?
Does compartmentalization of the replication process keeps the viral RNA in double
membrane vesicles and away from the sensing machinery of the host or does an active
process of antagonism block sensing of incoming viral genomes? Do these key viral
mediators function as virulence alleles and influence disease outcomes?
3. Although coronavirus replicase proteins are highly conserved, the accessory proteins
are heterogeneous. Has each virus evolved a different set of IFN antagonizing proteins
or are there common mechanisms and protein(s) that functions as an antagonist during
coronavirus infection? How many viral antagonist of type I IFN are encoded in the
coronavirus genome? Are they species specific? What is their role in pathogenesis?
4. Why is 229E unique in its induction of IFN in culture while the other coronaviruses
do not? Does the availability of specific innate immune antagonists modulate the
pathogenesis of other human coronaviruses like NL63 and HKU1?
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5. Does SARS-CoV or other CoVs induce IFN in monocyte derived cells in a host? In
vitro the results are quite different depending on the cell type, origin and preparation.
What happens in vivo?
6. Are coronaviruses killed in MPs when they are engulfed during infection? Many
SARS-CoV infected lungs show MPs containing SARS-CoV particles. Is this a
mechanism for clearance of the virus or is SARS using the MP to evade the immune
system and carry the virus deeper into the lung tissue? Do coronaviruses have ways
of evading death induced by the MP? Are innate immune responses blocked in during
replication in the lung?
7. Are viral proteins acting as intracellular or extracellular IFN antagonists during
infection and what stages in the pathways are targeted for inactivation?
8. How does aging impact the innate immunity response and contribute to the increased
pathogenesis noted in elderly patients following SARS-CoV infection?
It is anticipated that the interactions of coronavirus genomes and gene products with the host
innate immune system will provide a robust research agenda over the next several years,
yielding critical information that should elucidate many molecular mechanisms that contribute
to coronavirus virulence and pathogenesis in human and animal hosts.
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Figure 1. IFN sensing and signaling pathway
RNA viruses are internalized through several mechanisms, either fusion with the plasma
membrane or binding to a surface receptor (ACE2 for SARS-CoV, carcinoembryonic antigen-
related cell adhesion molecule 1 (CEACAM1) for MHV). That internalization exposes the
genomic RNA to the dsRNA sensing machinery in the cell; TLR3, RIGI and MDA5. These
proteins signal the IRF3 cascade leading to induction of IFNb and production of secreted
IFNβ protein. That IFNβ protein can then bind IFNα/β receptors (INFAR1) on the surface of
the same cell or surrounding cells. This activates the Stat1 signaling pathway to activate the
many anti-viral genes found with ISRE promoter elements.
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Figure 2. Lack of an IFN beta induction by SARS-CoV
SARS-CoV was tested for its ability to activate an IFN beta promoter by transfection of 293T
cells with a plasmid containing the IFNβ promoter driving expression of firefly luciferase.
After 24 hours post-transfection either PBS, SARS-CoV or Sendai Virus was added at an MOI
of 5. Samples were taken at 8, 24, 36 and 48 hours post infection and analyzed for luciferase
production. We find no induction of IFNβ resulting from SARS-CoV infection however a
robust expression level is seen in the Sendai virus infected cells. The depletion of luciferase
seen in the Sendai infections after 24 hours is due to cell death.
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Figure 3. Lack of Type I IFN secreted from infected cells
A Type I IFN bioassay was performed on media from infected MA104 cells (IFN competent
for signaling and production). Cells were infected with an MOI of 5 for either SARS-CoV
strains TOR2 and Urbani. Parainfluenza Virus was used as a positive control. Over a timecourse
of 2, 24 and 48 hours of infection no Type I IFN was produced from SARS-CoV infected cells
while PIV produced large amounts of IFN. LOD means level of detection for the assay.
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Figure 4. Real-time PCR for innate immune response genes
Caco2 cells were infected with the infectious clone for SARS-CoV (icSARS), the Urbani strain
of SARS or Sendai Virus at an MOI of 5 for each. After 18 hours cells were harvested for RNA
extraction and used for Real time analysis of the denoted genes. Low levels expression was
seen in SARS-CoV infected samples for IFNα, IFNβ, IL6 and IL8 although large inductions
were seen in the Sendai Virus infected samples. Mx was found to be induced by all 3 viruses
to a very large extent while IP-10 was increased up to 100 fold for SARS infected cells and
minimal for Sendai infection. All expression levels are shown relative to an 18S standard.
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Figure 5. A. SARS-CoV genome organization
The SARS-CoV genome is shown divided into 2 main regions, the Replicase consisting of
ORFs 1a and 1b and the Subgenomic ORFs comprising the structural and accessory ORFs.
B. Generation of SARS-CoV infectious clone. The SARS-CoV genome is broken into 6
fragments noted A through F. Each fragment is cloned so as to encode a type II restriction site
at either end allowing for directed ligation of all fragments while not changing the amino acids
of the encoded proteins. The plasmids are digested and ligated all together to form a single
30kb fragment. This is used as the template for transcription by T7 polymerase which the 5′
most piece has a start site encoded in it. The resulting RNA is electroporated into Vero cells
and virus is collected in the media 24 hours after electroporation.
Frieman et al. Page 20
Virus Res. Author manuscript; available in PMC 2009 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. The coronavirus life cycle
Coronavirus entry is mediated by binding of S glycoprotein to the ACE2 receptor, cleavage
by cathepsin L and activation of a fusion peptide in S2 that mediates entry via fusion through
endocytic compartments [1]. Following fusion with the endosomal compartment the viral
genome release into the cytosol where it is translated into the viral replicase proteins ORF1a
and 1b[2]. These polyproteins are then cleaved by 2 proteases, Main Protease (Mpro) and
Papain like protease, PLP, into the individual proteins necessary for replication[3].
Subgenomic RNA synthesis occurs from discontinuous transcription which joins leader RNA
sequences encoded at the 5′ end of the genome to the body sequences of each subgenomic
RNA. The eight different subgenomic negative strands serve as template for the synthesis of
like sized subgenomic mRNA.[4] Subgenomic RNAs are then translated into viral proteins
which localize to their relevant compartments. [5] Assembly of virions occurs in an ERGIC
like compartment in the cell. Here S, E, M and N bound to genomic viral RNA are assembled
into virions in vesicles. [6] The vesicles are then exported to the cell surface where fusion
occurs with release of virions into the exterior environment. [7,8]
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Figure 7. SARS does not block NFκB and IFNβ promoter induction
Vero cells were transfected with either plasmids containing the NFκB (A) or the IFNβ (B)
promoter promoter expressing luciferase. 24 hours post transfection cells were infected with
the designated viruses. 12 hours post infection cells were then infected with Sendai Virus and
luciferase was assayed 6 hours later using Steady-Glo Luciferase Reagent (Promega).
Triplicate wells were averaged and then compared to mock infected wells to graph the fold
induction values.
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Figure 8. SARS-CoV ORF6 blocks nuclear import of Stat1
A. 293 cells were transfected with a plasmid containing an ISRE promoter driving luciferase
and either CAGGS/GFP or CAGGS/ORF6. 24 hours post transfection half of the wells were
treated with IFNβ for 4 hours and then assayed by Steady-Glo Luciferase Reagent (Promega)
for ISRE promoter induction. B. 293 cells were transfected with HA tagged ORF6. 24 hours
post transfection cells were treated with 100IU/ml of IFNβ for 1 hour. Cells were then lysed
and assayed by western blot for the presence of total STAT1 (top panel) or phosphorylated
STAT1 (bottom panel). C. Vero cells were transfected with either STAT1/GFP alone or co-
transfected with the designated plasmids for 24 hours. After 24 hours, cells were either
untreated or treated with IFNβ or IFNγ as designated. Notice STAT1 is cytoplasmic when
untreated but is transported to the nucleus when treated with either IFNβ or IFNγ Co-expression
of SARS ORF6 retains STAT1 in the cytoplasm while SARS 3a expression does not. Also
notice that SARS ORF6 blocks IFNγ induced STAT1 nuclear translocation as well.
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Table 1
Summary of selected papers cited in this review.
Author Cells Results Type I IFN↑
Zhang et al. PBMC from infected patients IL-6↑, IL-10↑, IL-4↑, IFNγ↑, IL-8↓, TGF-
beta↓
ND
Regunathan et al. PBMC from infected patients IP-10↑, IL-6↑, IL-8↑, MCP-1↑ ND
Castilletti et al. Ex vivo infected PBMCs IFNα ↑, IFNβ↑ Yes
Law et al. Ex vivo infected DCs IP-10↑, MIP1α↑, Rantos↑, MCP-1↑ ND
Tang et al. Huh7 cells No IFNα and IFNβ induction No
Cinatl et al. Caco2 and CL-t4 CXC chemokines↑, OAS2↑, IL-18↓, MIF↓ No
Speigel et al. Caco2 and 293 IP-10↑, IL-8↑ both ↑ in Caco2 but not 293 No
Okabayashi et al. Caco2 IFNα↑, IFNβ↑, IRF7 ↑, OAS ↑ … Yes
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